The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool

The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool

Authors

  • Marc A. Judson Chief, Division of Pulmonary and Critical Care Medicine Department of Medicine, MC-91 Albany Medical College
  • Ulrich Costabel
  • Marjolein Drent
  • Athol Wells
  • Lisa Maier
  • Laura Koth
  • Hidenobu Shigemitsu Professor of Medicine Chief, Division of Pulmonary & Critical Care Medicine University of Nevada School of Medicine 2040 Charleston Blvd. Suite 300 Las Vegas, NV 89102
  • Dan A. Culver
  • Jeffrey Gelfand
  • Dominique Valeyre
  • Nadera Sweiss
  • Elliott Crouser
  • Adam S. Morgenthau
  • Elyse E. Lower
  • Arata Azuma
  • Mami Ishihara
  • Shin-ichiro Morimoto
  • Tetsuo Tetsuo Yamaguchi
  • Noriharu Shijubo
  • Jan C. Grutters
  • Misha Rosenbach
  • Hui-Ping Li
  • Paola Rottoli
  • Yoshikazu Inoue
  • Antje Prasse
  • Robert P. Baughman
  • The WASOG Sarcoidosis ORGAN ASSESSMENT INSTRUMENT INVESTIGATORS

Keywords:

sarcoidosis, organ, diagnosis, consensus

Abstract

Introduction: A Case Control Etiology of Sarcoidosis Study (ACCESS) sarcoidosis organ assessment instrument has been used for more than a decade to establish uniform standards for the probability of sarcoidosis organ involvement. The ACCESS instrument has become increasingly outdated as new technologies have been developed. Furthermore, the ACCESS instrument failed to address all possible organs involved with sarcoidosis. For these reasons, the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) developed a new sarcoidosis organ assessment instrument.

Methods: Clinical sarcoidosis experts assessed various clinical manifestations for the probability of sarcoidosis organ involvement. Two criteria were required to apply this assessment: 1) histologic evidence of granulomatous inflammation of unknown cause in an organ that was not being assessed; 2) the clinical manifestation being addressed required that alternative causes other than sarcoidosis had been reasonably excluded. Clinical manifestations were assessed as either: a) highly probable: likelihood of sarcoidosis causing this manifestation of at least 90%.; b) probable: likelihood of sarcoidosis causing this manifestation of between 50 and 90%; c) possible: likelihood of sarcoidosis causing this manifestation of less than 50%. The sarcoidosis experts voted on the likelihood of sarcoidosis causing each manifestation using Delphi study methodology where at least 70% agreement of the experts was needed for consensus.

Results: Various clinical manifestations were classified as highly probable, at least probable, possible, or indeterminate when no consensus could be reached.

Conclusion: An instrument was developed by expert opinion that may be useful for the clinician and researcher in establishing criteria for sarcoidosis organ involvement.

Author Biography

Marc A. Judson, Chief, Division of Pulmonary and Critical Care Medicine Department of Medicine, MC-91 Albany Medical College

Professor of Medicine

Chief, Division of Pulmonary and Critical Care Medicine

Albany Medical College

Downloads

Published

18-04-2014

Issue

Section

Original Articles: Clinical Research

How to Cite

1.
Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2014 Apr. 18 [cited 2025 Mar. 22];31(1):19-27. Available from: https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/3218